RED HOT Contributors

 

STAT Plus: Q&A: At GE Healthcare, why making biologics can be like craft brewing

0
CREDIT: This post was originally published on this site

J

ohn Flannery, CEO of GE Healthcare, has worked for General Electric for 30 years, but moved into health care only two-and-a-half years ago. He has had significant success since then, turning a division that was large but stagnant into an $18 billion money-maker. He talked recently with STAT about building a biopark, why applying data analytics to production is like craft brewing, and how his business is expanding into the developing world. This interview has been edited and condensed.

You’ve said that about half your business involves selling equipment and services to the biological drug production industry. What does that entail?

Seven or eight of the top 10 drugs now are biologic drugs. We have a role in supporting all of those drugs. We work closely with the drug companies and pharma companies as they’re researching and developing these drugs. The production process is really an integral part of the final approval of the drug itself, so we stay with these companies for years after these drugs come to market. It’s a good growth business for us.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

About

We Support OUR Contributors

Get Our Newsletter

 Receive podcast updates
Exclusive insights
Patient Engagement Tips from industry experts
We hate SPAM as much as you do and promise to keep your email address safe.
  • Subscribe to the Podcast